Muutke küpsiste eelistusi

Telehealth in Urology [Pehme köide]

(Director of Clinical Trials & Innovation, Assistant Professor of Urology, Icahn School of Medicine at Mount Sinai, New York, New York)
  • Formaat: Paperback / softback, 146 pages, kõrgus x laius: 235x191 mm, kaal: 320 g
  • Ilmumisaeg: 29-Nov-2022
  • Kirjastus: Elsevier - Health Sciences Division
  • ISBN-10: 0323874800
  • ISBN-13: 9780323874809
Teised raamatud teemal:
Telehealth in UrologySuurem pilt
  • Formaat: Paperback / softback, 146 pages, kõrgus x laius: 235x191 mm, kaal: 320 g
  • Ilmumisaeg: 29-Nov-2022
  • Kirjastus: Elsevier - Health Sciences Division
  • ISBN-10: 0323874800
  • ISBN-13: 9780323874809
Teised raamatud teemal:
Püsilink: https://www.kriso.ee/db/9780323874809.html
Märksõnad:
Offering significant benefits to both healthcare providers and patients, telehealth is a key component in the future of urology and patient care. Telehealth in Urology is a step-by-step, illustrated guide for clinicians who are beginning a telehealth offering or are interested in adopting new digital technologies—all specific and relevant to today’s urology practice. It covers the key information you need to know—from necessary equipment to the practice team—with clear explanations of how you can best use telemedicine to provide timely, effective care to every patient.

  • Explains how to establish and conduct telehealth consultations and describes the growing number of options in telehealth diagnostics, patient monitoring, and digital therapeutics.

  • Offers practical examples of conducting telehealth visits for common adult and pediatric urological complaints, for both benign and malignant conditions.

  • Guides readers step by step through the many practical challenges of telemedicine for clinicians, patients, and practices, and describes the opportunities that lay ahead for the field.

  • Covers regulatory, compliance, and technical principles of telehealth devices and applications for use in urology, including key topics such as data protection, patient privacy, e-prescribing, remote diagnostics and monitoring, and much more.

PART 1 Regulations concerning telehealth provision
Chapter 1 Regulations and requirements for telehealth provision
3(12)
Introduction
3(1)
Regulation of telemedicine in the European Union
4(1)
Federal US legislation relevant to the practice of telehealth in the United States
5(1)
Medicare Telehealth Services Flexibility Act (MTSFA)
5(1)
Federal communication commission's rural health care program
6(1)
Federal communications commission rules governing telehealth provision in the United States
7(1)
Requirements for telehealth
8(1)
Licensing
8(1)
Medical malpractice insurance
8(1)
Clinician--patient relationship
8(1)
Online prescribing
9(1)
Informed consent
9(1)
Reimbursement and telehealth billing and payments
10(1)
Infrastructure
11(2)
Bibliography
13(2)
Chapter 2 Patient privacy laws
15(50)
Introduction
15(1)
Potential privacy risks
16(1)
Privacy controls in the USA
17(2)
There will ultimately be further privacy laws implemented, so watch this space
19(2)
European regulations and laws
21(1)
GDPR--general data protection regulation
22(1)
Data protection directive--passed October 24, 1995
22(1)
EU e-privacy directive
23(1)
Conclusions
23(1)
Bibliography
24(33)
3 Define the vision and develop change initiatives to capitalize on adopting telehealth
55(1)
4 Engage key stakeholders and "enlist a volunteer army"
55(1)
5 Remove barriers and empower all stakeholders
56(1)
6 Generate and celebrate short-term wins
56(1)
7 Consolidate gains and produce more change
56(1)
8 Institutionalize this change culture
57(1)
Implementation strategy
57(1)
Proactive versus reactive technical support for patients
58(1)
Engage patients with telemedicine
59(1)
Sample information physicians can share with patients to help them understand the value of telemedicine/teleurology
60(1)
Bibliography
61(4)
PART 3 What telehealth tools are available for urology?
Chapter 6 Telehealth tools, conducting a consultation and the ethical practice of telemedicine
65(10)
Introduction
65(1)
The patient--doctor relationship
65(2)
Virtual phone
67(1)
Online patient web portal
67(1)
Video chat platforms
68(1)
Conducting a consultation
69(1)
The ethical practice of telehealth
70(1)
Autonomy
70(1)
Beneficence
71(1)
Nonmaleficence
72(1)
Justice
72(1)
Bibliography
73(2)
Chapter 7 Remote diagnostics in urology
75(14)
Introduction
75(1)
Ideal characteristics of medical conditions amenable to telediagnosis
75(3)
Symptom diaries, questionnaires, and recording subjective assessments
78(1)
Blood tests
79(1)
Kits sent by mail
80(1)
Lateral flow tests (LFT) for immediate results
80(1)
PSA kits
80(1)
Testosterone
81(1)
Creatinine and eGFR estimation
81(1)
Any blood test
82(1)
STI checks
82(1)
Urine
82(1)
Dipstick urinalysis/apps
82(1)
Flow rates/basic urodynamics
83(1)
Diagnostic imaging
84(1)
Ultrasound and PVR
84(1)
Advanced imaging
84(1)
Conclusions
85(1)
Bibliography
86(3)
Chapter 8 Remote patient monitoring in urology
89(12)
Introduction
89(1)
Benefits of remote monitoring
90(1)
Prevent readmissions
90(1)
Improve patient care
91(2)
Wearables and devices
93(1)
Remote patient monitoring postoperatively
94(4)
Bibliography
98(3)
Chapter 9 Digital therapeutics
101(10)
Introduction
101(1)
Regulatory considerations for digital therapeutics
102(1)
Digital therapeutics in urology
103(1)
Example use cases of digital therapeutics
103(1)
Preventative care
103(1)
Preoperative assessment
104(1)
Managing chronic conditions
104(2)
Digitally enabled treatments
106(1)
Barriers to adoption
107(2)
Bibliography
109(2)
Chapter 10 Remote surgery
111(10)
Introduction
111(1)
History of robotic surgery
112(3)
Telementoring
115(1)
Telesurgery
116(1)
World's first telesurgery service
116(1)
Considerations on licensing and malpractice insurance for the "telesurgeon"
117(1)
Challenges for telesurgery
117(2)
Conclusion
119(1)
Bibliography
119(2)
Chapter 11 E-prescribing
121(10)
Introduction
121(2)
E-prescribing--a tool to address the large burden of urological disease and the limited workforce?
123(1)
Opportunities fore-prescribing
124(1)
Drug misuse and diversion in urology is not a new problem
125(2)
Challenges to e-prescribing
127(1)
Maintaining complete medication lists
127(1)
Limited use of clinical decision support
128(1)
Obtaining accurate patient-specific formulary information
129(1)
Case examples--sexual health & erectile dysfunction
129(2)
Bibliography 131(2)
Index 133
Dara Lundon - Dr.Lundon MD MBA PhD is Director of Clinical Trials and Innovation at the Icahn School of Medicine at Mount Sinai New York. Dr. Lundon graduated from The School of Medicine at University College Dublin where he was admitted as an Entrance Scholar for outstanding academic achievement. He undertook his residency in Ireland and subsequently completed his Ph.D in Prostate Cancer Biology under the supervision of Professor R.W.G Watson and the late Professor John M. Fitzpatrick. Dr. Lundon received a scholarship to the NCI Cancer Prevention Program at the NIH in Bethesda MD and completed a fellowship in NYU under the supervision of Professor Stacy Loeb. Dr. Lundon completed an MBA and was an analyst on the number 1 ranked team on Wall Street in Large Cap Pharma, Biotech and Specialty Pharma. Prostate biopsy is an invasive procedure with a risk of significant morbidity. Dr. Lundon's clinical research work has translated discoveries from bench to bedside and helped reduce the number of unnecessary prostate biopsies in men As well as other yet to be confirmed subject matter experts for each volume